A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...
A personalized mRNA cancer vaccine developed by Moderna and Merck — when combined with the immunotherapy drug Keytruda — ...
South Korea's Penetrium Bioscience said Wednesday that the company would start a clinical test combining its investigational ...
Morning Overview on MSN
An mRNA vaccine paired with Keytruda cut melanoma recurrence by nearly 50% over five years in a landmark NYU-led trial
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw their risk of disease recurrence cut by nearly half over five years, ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
A recent cross-border investigation examines how aggressive drug pricing and patent strategies drive up costs and limit ...
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results